Clinical effect of Xiaoaiping Injection combined with gemcitabine and carboplatin in treatment of ⅢB and Ⅳ non-small cell lung cancer
10.7501/j.issn.1674-6376.2017.02.026
- VernacularTitle:消癌平注射液联合吉西他滨和卡铂治疗ⅢB和Ⅳ期非小细胞肺癌的临床评价
- Author:
Xiaolin HU
;
Xisong LIU
;
Xiding CHEN
- Keywords:
Xiaoaiping Injection;
gemcitabine;
carboplatin;
non-small cell lung cancer;
clinical effect
- From:
Drug Evaluation Research
2017;40(2):262-265
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical effect of Xiaoaiping Injection combined with gemcitabine and carboplatin in the treatment ofⅢB and Ⅳ non-small cell lung cancer (NSCLC).Methods Totally 106 NSCLC patients from Huangshi Central Hospital of Edong Medical Group were sellected in this study.The patients were divided into gemcitabine and carboplatin control group (n =53)and Xiaoaiping Injection combined with gemcitabine and carboplatin observation group (n =53).The clinical efficacy and adverse reactions were compared between two groups.Results After four cycles of treatment,the effective rate and control rate in observation group were 39.6％ and 77.4％,and those in control group were 35.8％ and 75.5％.There was no significant difference between the two groups.The decline rates of white blood cells,hemoglobin,and platelet in observation group were 41.5％,37.7％,and 45.3％,which were significantly lower than those of 64.2％,62.3％,and 69.8％ in control group (P ＜ 0.05).There was no significant difference of renal function injury,liver function damage,nausea,vomiting,dizziness,headache,diarrhea,and constipation between two groups.In observation group,the median survival time was 8.4 months,time to tumor progression was 5.3 months,and 1 year survival rate was 26.4％.In control group,the median survival time was 7.7 months,time to tumor progression was 4.2 months,and 1 year survival rate was 11.3％.There was significant difference between two groups (P ＜ 0.05).Conclusion Xiaoaiping Injection combined with gemcitabine and carboplatin can reduce the hematologic toxicity of chemotherapy drug in the treatment of ⅢB and Ⅳ NSCLC,and improve long-term clinical outcomes.combined with gemcitabine and carboplatin can reduce the hematologic toxicity of chemotherapy drug in the treatment ofⅢB and Ⅳ NSCLC,and improve long-term clinical outcomes.
